Conmed Corp (CNMD) Misses Q2 EPS by 1c; Guides
Get Alerts CNMD Hot Sheet
Price: $49.25 -0.38%
Revenue Growth %: -0.5%
Financial Fact:
Net Income Basic: 0.26
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: -0.5%
Financial Fact:
Net Income Basic: 0.26
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Conmed Corp (NASDAQ: CNMD) reported Q2 EPS of $0.43, $0.01 worse than the analyst estimate of $0.44. Revenue for the quarter came in at $193 million versus the consensus estimate of $193.55 million.
Conmed Corp sees FY2013 EPS of $1.80-$1.85, versus prior guidance of $1.80-$1.90 and the consensus of $1.86. Conmed Corp sees FY2013 revenue of $770-775 million, versus prior guidance of $770-780 million.
Conmed Corp sees Q2 2013 EPS of $0.37-$0.42, versus the consensus of $0.42. Conmed Corp sees Q2 2013 revenue of $184-189 million, versus the consensus of $186.3 million.
For earnings history and earnings-related data on Conmed Corp (CNMD) click here.
Conmed Corp sees FY2013 EPS of $1.80-$1.85, versus prior guidance of $1.80-$1.90 and the consensus of $1.86. Conmed Corp sees FY2013 revenue of $770-775 million, versus prior guidance of $770-780 million.
Conmed Corp sees Q2 2013 EPS of $0.37-$0.42, versus the consensus of $0.42. Conmed Corp sees Q2 2013 revenue of $184-189 million, versus the consensus of $186.3 million.
For earnings history and earnings-related data on Conmed Corp (CNMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Investing.com’s stocks of the week
- Bristol Myers Squibb MS CAR T therapy data shows patients off DMTs
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share